SynthesisInternational journal of cancer2022
A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups.
Synthesis in International journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.
- Assessing the Potential of HPV16 E6 Seroprevalence as a Biomarker for Anal Dysplasia and Cancer Screening-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- Home-based self-sampling vs clinician sampling for anal precancer screening: The Prevent Anal Cancer Self-Swab Study.International journal of cancer · 2023Trial
- Extended High-Risk HPV Genotyping With BD Onclarity Enhances Anal Cancer Screening Among High-Risk Populations: A Cross-Sectional Study.Diagnostic cytopathology · 2026Article
- Elimination of HPV-associated cancers: universal HPV vaccination and the role of anal screening - a meeting report.BMC proceedings · 2026Article
- Genotyping and Cytology Co-Testing for Anal Cancer Screening: Exploratory Evaluation of Cumulative HPV Genotype Burden as a New Potential Marker for Risk Stratification.Diagnostics (Basel, Switzerland) · 2026Article
- Risk stratification and anal cancer screening in immunocompetent women with genital HPV: Value of multicentric HSIL and performance of HPV-based screening.International journal of cancer · 2026Article
- Anal HPV in Kidney Transplant Recipients: A Closer Look at Pathogenesis and Clinical Management.Pathogens (Basel, Switzerland) · 2026Review
- Evaluation of Anal Cancer Screening Among 18-to-34-Year-Old Men Who Have Sex With Men Living With HIV Over a 10-Year Period.Open forum infectious diseases · 2026Article
- Incidence and burden of anal cancer-time to fight the growing disparities.ESMO gastrointestinal oncology · 2026Review
- Bidirectional Interactions Between Cervicovaginal Microbiota and Human Papillomavirus Drive Persistence and Disease Progression.International journal of molecular sciences · 2026Review
- Willingness to Undergo Human Papillomavirus Testing Among Men Who Have Sex With Men in China Based on the Information-Motivation-Behavioral Skills Model: Online Cross-Sectional Study.JMIR public health and surveillance · 2026Article
- High prevalence of anal HPV16 infection among HIV-negative men who have sex with men and transgender women using pre-exposure prophylaxis: a single-centre retrospective cross-sectional study.New microbes and new infections · 2026Article
- Liquid Biopsy of HPV Cell-Free DNA Enables Blood-Based Early Detection and Molecular Stratification of HPV-Associated Cancer and Precancer Stages.medRxiv : the preprint server for health sciences · 2026Article
- Concordance and Acceptability of Self- Vs. Clinician-Collected Anorectal Swabs for HPV Genotyping in Gay, Bisexual and Other Men Who Have Sex With Men in Metropolitan Barcelona.Journal of medical virology · 2026Article
- Anal high-grade squamous intraepithelial lesions: identification, classification, and management.The British journal of surgery · 2026Review
- Anal Dysplasia: A Review of Pathology with Focus on Current Terminology, Pathologic Diagnosis, and Diagnostic Challenges.Clinics in colon and rectal surgery · 2026Review
- Anal Dysplasia: Epidemiology, Risk Factors, and Progression to Malignancy.Clinics in colon and rectal surgery · 2026Review
- Stratifying the risk of anal high-grade squamous intraepithelial lesion among immunosuppressed women with genital HPV.Frontiers in immunology · 2026Article
- Swab-based anal cancer screening in men living with HIV: Projected outcomes for different screening algorithms.International journal of cancer · 2025Article
- ADAR1 mRNA quantification for predicting HSIL in persons with HIV and abnormal anal cytology.International journal of cancer · 2025Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
Abstract
To inform optimal approaches for detecting anal precancers, we performed a systematic review and meta-analysis of the diagnostic accuracy of anal cancer screening tests in different populations with elevated risk for anal cancer. We conducted a literature search of studies evaluating tests for anal precancer and cancer (anal intraepithelial neoplasia grade 2 or worse, AIN2+) published between January 1, 1997 to September 30, 2021 in PubMed and Embase. Titles and abstracts were screened for inclusion and included articles underwent full-text review, data abstraction and quality assessment. We estimated the prevalence of AIN2+ and calculated summary estimates and 95% confidence intervals (CI) of test positivity, sensitivity and specificity and predictive values of various testing strategies, overall and among population subgroups. A total of 39 articles were included. The prevalence of AIN2+ was 20% (95% CI, 17-29%), and ranged from 22% in men who have sex with men (MSM) living with HIV to 13% in women and 12% in MSM without HIV. The sensitivity and specificity of cytology and HPV testing were 81% and 62% and 92% and 42%, respectively, and 93% and 33%, respectively for cytology and HPV co-testing. AIN2+ risks were similar among those testing positive for cytology, HPV, or co-testing. Limited data on other biomarkers (HPV E6/E7 mRNA and p16/Ki-67 dual stain), suggested higher specificity, but lower sensitivity compared with anal cytology and HPV. Our findings provide important evidence for the development of clinical guidelines using anal cytology and HPV testing for anal cancer screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.